Skip to main content
Premium Trial:

Request an Annual Quote

Luxembourg Center Taps Biobase to Analyze NGS Variants for Clinical Diagnostics


Biobase said this week that the Luxembourg Center for Systems Biomedicine will use its Genome Trax software to analyze next-generation sequencing data for use in clinical diagnostics.

Additionally, Biobase said that it will work with LCSB to establish “a hub of expertise” for the application of the company’s products and to provide data analysis, training, and support to researchers in Luxembourg and surrounding countries.

In a statement, Reinhard Schneider, who heads the bioinformatics core facility at LCSB, said that the mutation, regulation, and pharmacogenomics data in Genome Trax are “crucial for the annotation of our clinical data.”

He described LCSB’s collaboration with Biobase “as a strategic partnership to advance the clinical application of NGS technology."

Genome Trax helps users prioritize human genome variants in whole-genome or exome data. The tool maps NGS data to known features such as disease mutations and regulatory sites, allowing users identify novel mutations that could affect the function of candidate disease genes.

Filed under

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.